Company intelligence / Profile preview

iCAD

Nashua, NH, United Statesicadmed.com ↗

Ownership: Public · ICAD
Employees: ~67
Development stage: Commercial

Overview

iCAD provides FDA-cleared, CE-marked AI-powered solutions for early breast cancer detection, density assessment, and risk evaluation. Its flagship product suite—ProFound—has been used to analyze over 40 million mammograms worldwide in the last five years. Clinical evidence supports improved accuracy in detecting cancers earlier with reduced reading time for radiologists. The company’s solutions are available in over 50 countries and trusted by thousands of providers serving millions of patients.

Therapeutic areas: Women's HealthOncologyCardiovascular
Modalities: Device (AI-powered diagnostic software)Non-pharmacological therapy (for radiotherapy subsidiary Xoft)Artificial intelligence solution
Industry: Medical Imaging

Financials

Market cap: $106.3M
Total revenue: $4.9M
Enterprise value: $86.6M

Beyond the preview

Go deeper on iCAD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iCAD.

Explore the full profile